In the context of contemporary pharmacotherapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been well established.
creased upfront utilization of oral P2Y 12 receptor antagonists, and introduction of more potent antiplatelet and anticoagulants (including bivalirudin) have attenuated the overall benefits of GPIs observed in prior studies. [4] [5] [6] Furthermore, selective GPI utilization in high-risk patients, coupled with other contemporary means of reducing bleeding risk (including greater use of transradial access), have improved the safety and tolerability of these agents. 7 As such, a reappraisal of the role of GPIs in the background of currently available pharmacotherapies is required.
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Cangrelor is a novel, fast-onset, fast-offset, potent, intravenous P2Y 12 antagonist. [9] [10] [11] [12] The Cangrelor vs Standard
Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) program 13, 14 collectively demonstrated that cangrelor reduces ischemic complications up to 30 days following PCI compared with clopidogrel or placebo without increasing Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-defined severe/life-threatening bleeding 15 or requirement for blood transfusions. These data formed the basis for the recent approval of cangrelor for use in elective or urgent PCI in the United States and Europe. To our knowledge, no study to date has evaluated the comparative efficacy and safety of more potent P2Y 12 inhibitors, such as cangrelor, with GPIs. In this exploratory pooled analysis of individual patient-level data from the 3 phase 3 CHAMPION trials (CHAMPION PHOENIX, 14 CHAMPION PLATFORM, 16 and CHAMPION PCI 17 ), we compared ischemic and bleeding risks in patients assigned to cangrelor but not receiving GPIs with patients assigned to clopidogrel and receiving planned routine GPIs.
Methods

The CHAMPION Program
The study designs and primary results 14, 16, 17 of each of the CHAMPION trials have been reported previously. The present study's data analysis was conducted from October 28, 2015, to August 6, 2016. In brief, patients 18 years or older who required PCI for stable angina, non-ST-segment elevation acute coronary syndrome (NSTE-ACS), or ST-segment elevation MI (STEMI) were eligible for enrollment. Patients who had received P2Y 12 antagonists or abciximab within 5 to 7 days or eptifibatide, tirofiban hydrochloride, or fibrinolytic therapy within 12 hours before randomization were excluded (except in CHAMPION PCI, 17 in which prestudy use of clopidogrel at doses ≤75 mg/d was permitted). Trial protocols were approved by the institutional review boards or ethics committees at each participating center (eAppendix in the Supplement); the present study was included within that approval. All patients provided written informed consent for participation.
Each of the CHAMPION clinical trials 14, 16, 17 was prospective, double-blind, double-dummy, and randomized; patients were randomized to receive cangrelor or clopidogrel. Cangrelor or matching placebo was administered as a 30-μg/kg intravenous bolus followed by a 4-μg/kg/min infusion for at least 2 hours or for the duration of PCI, whichever was longer. Clopidogrel (600 mg) was administered to all patients in the cangrelor arm at the end of the infusion. In the comparator arm, clopidogrel (300 or 600 mg) was given to patients at the beginning of PCI (CHAMPION PCI), 17 at the end of PCI (CHAMPION PLATFORM), 16 or at the start or end of PCI based on the study site standard of care (CHAMPION PHOENIX). 14 Aspirin (75-325 mg) and clopidogrel (75 mg/d) were administered to all patients during the first 48 hours. Dual antiplatelet therapy after 48 hours, periprocedural anticoagulation, choice of stent and access site, and sheath management protocol were left to the discretion of individual site investigators.
tor. To minimize indication bias and confounding, patients requiring bailout or rescue GPI therapy were excluded from the present analysis. In this post hoc analysis, patients randomized to cangrelor who did not receive GPIs (cangrelor alone group) were compared with patients randomized to clopidogrel (or placebo) who received routine GPIs (clopidogrel-GPI group). All patients in the clopidogrel-GPI group received GPIs as a planned strategy at the discretion of the site investigator.
Statistical Analysis
Baseline characteristics and efficacy and safety end points at 48 hours were compared between the cangrelor alone and clopidogrel-GPI groups. To account for differences in baseline risk profiles and confounding by indication, a propensity score (PS)-matched analysis was undertaken. Logistic regression modeling calculated the PS for each patient, representing the probability of receiving a GPI conditional on the following covariate set: age, sex, weight, region (United States vs non-United States), indication for PCI (stable angina, NSTE-ACS, and STEMI), abnormal levels of cardiac biomarkers, stent type, prior thienopyridine exposure, prior stroke or transient ischemic attack, medical history (diabetes, heart failure, and peripheral artery disease), planned clopidogrel loading dose (300 or 600 mg), and periprocedural heparin or bivalirudin. Variables chosen for PS determination were those with a significance level of P < .15 for baseline comparisons. Patients in the cangrelor alone and the clopidogrel-GPI groups were matched 1:1 using nearest-neighbor matching without replacement, with caliper width of 0.2 times the SD. 22 Adequacy of matching was tested using the standard differences method, and values less than 10% reflect more balanced matched groups. Primary and secondary efficacy and safety outcomes were compared between the 2 matched cohorts using conditional logistic regression. Ischemic and bleeding end points were also combined to determine net clinical benefit of each antiplatelet approach. Because CHAMPION PCI was the only trial that allowed for GPI utilization for any indication, additional sensitivity analyses were performed to test the comparability of the CHAMPION PCI sample to the overall results of the pooled analysis. Patients in the cangrelor alone and the clopidogrel-GPI groups were rematched based on calculated PS within the mITT population of the CHAMPION PCI alone. Baseline characteristics and clinical outcomes were compared between the new matched pairs in CHAMPION PCI. Continuous variables are presented as mean (SD) or as median (interquartile range) and were compared using t tests or Wilcoxon rank sum tests, as appropriate. Categorical variables are presented as number (percentage) and were compared using χ 2 testing or Fisher exact tests, as appropriate. Logistic regression analyses were used to calculate effect sizes in both the original and PS-matched cohorts; the effect sizes are expressed as odds ratios (ORs) and associated 95% CIs. All statistical tests were 2-tailed with a level of significance of P < .05, and statistical analyses were performed using SAS, version 9.3 (SAS Institute Inc).
Results
Across the mITT populations of the 3 CHAMPION trials (N = 24 902), 3173 patients (12.7%) received a GPI during hospitalization, of whom 745 (23.5%) received GPIs for bailout or rescue purposes and thus were excluded from the present analysis. A total of 12 140 patients were included in the analysis; 8779 were men (72.3%), and the mean (SD) age was 63.2 (11.3) years. Of the total mITT population, 10 929 patients were assigned to the cangrelor arm and did not receive a GPI (cangrelor alone group), and 1211 patients were assigned to clopidogrel (or placebo) and received routine GPI (clopidogrel-GPI group). Most patients in the clopidogrel-GPI cohort received eptifibatide (941 [77.7%]), 176 (14.5%) received abciximab, and 91 (7.5%) were given tirofiban; the specific GPI used was not reported in 3 patients.
Baseline Patient Profiles
There were baseline discrepancies in patient profiles between the 2 selected cohorts ( Table 1) . Patients in the clopidogrel-GPI group were more likely to be male, younger, and enrolled from the United States compared with those in the cangrelor alone group. The clopidogrel-GPI cohort also presented for PCI more frequently for NSTE-ACS and STEMI and were more likely to receive drug-eluting stents. However, patients in the clopidogrel-GPI cohort had a lower comorbid disease burden (diabetes, heart failure, and peripheral artery disease) and were more likely to receive a planned clopidogrel loading dose of 600 mg. Patients in the cangrelor alone group were more likely to receive bivalirudin compared with those in the clopidogrel-GPI group. tween the cangrelor alone and clopidogrel-GPI groups. However, patients in the cangrelor alone cohort experienced consistently lower crude rates of safety end points, assessed by all bleeding indices and blood transfusion requirement (Table 3) .
In the final PS-matched end point analysis (Table 3) , rates of the primary efficacy end point were not significantly different between the cangrelor alone and clopidogrel-GPI groups (2.6% vs 3.3%; OR, 0.79; 95% CI, 0.48-1.32). Similarly, rates of the key secondary efficacy end point, stent thrombosis, were low in both cohorts and did not differ significantly by intravenous antiplatelet group (0.1% vs 0.6%; OR, 0.17; 95% CI, 0.02-1.38).
There were numerically (but not statistically) lower rates of GUSTO-defined severe/life-threatening bleeding (0.3% vs 0.7%; OR, 0.43; 95% CI, 0.11-1.66) and GUSTO-defined moderate or severe/life-threatening bleeding (1.2% vs 2.3%; OR, 0.50; 95% CI, 0.24-1.03) with cangrelor alone compared with clopidogrel-GPI. Rates of TIMI-defined major or minor bleeding were significantly lower in patients receiving cangrelor alone compared with patients receiving clopidogrel-GPI (0.7% vs 2.4%; OR, 0.29; 95% CI, 0.13-0.68). Similarly, the cangrelor alone cohort experienced lower rates of ACUITY-defined major bleeding compared with the clopidogrel-GPI cohort (3.6% vs 5.8%; OR, 0.61; 95% CI, 0.40-0.94). Furthermore, blood transfusion requirement was lower in the cangrelor alone group compared with the clopidogrel-GPI group (1.0% vs 2.1%; OR, 0.45; 95% CI, ). In the analysis of net clinical benefit, the cangrelor alone group experienced numerically lower rates of combined primary ischemic and bleeding end points compared with the clopidogrel-GPI group (2.9% vs 3.8%; OR, 0.77; 95% b End points were assessed in patients included in the modified intention-to-treat population (comprising patients who underwent percutaneous coronary intervention and received the study drug).
c End points were assessed in patients who underwent randomization and received at least 1 dose of the study drug. A patient who did not complete the scheduled follow-up and experienced no event was not counted in the denominator.
Sensitivity Analysis
Dedicated sensitivity analysis was performed using patients included in the mITT population of the CHAMPION PCI trial alone. Subsequent PS matching yielded 665 unique matched pairs of patients enrolled in CHAMPION PCI. Major baseline characteristics were well balanced between the PS-matched cangrelor alone and clopidogrel-GPI groups in the CHAMPION PCI trial (eTable 1 in the Supplement). Similar patterns and trends were observed in efficacy and safety end points between the 2 selected groups in the CHAMPION PCI trial as in the overall pooled analysis of the 3 CHAMPION trials (eTable 2intheSupplement).
Discussion
In this exploratory analysis of the CHAMPION program, patients randomized to cangrelor who did not receive GPIs experienced similar periprocedural ischemic risks compared with patients randomized to clopidogrel who received routine GPIs (as a planned strategy). There were lower risk-adjusted bleeding risks in patients treated with cangrelor alone compared with those in the clopidogrel-GPI group, even after PS matching to account for baseline discrepancies in patient profiles.
Clinical Context and Implications
There is a continued unmet clinical need for potent but safe antithrombotic agents in contemporary PCI practice, 23 and the optimal approach to intensification of antiplatelet and antithrombotic therapy in high-risk patient scenarios remains to be determined. 
Limitations
To our knowledge, there are no randomized data available directly comparing these therapies. In the absence of randomized data, matched comparisons have been used as a validated alternative
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; however, as with all nonrandomized data, we may not be able to identify all relevant factors to facilitate adequate matching regardless of the methodology used. Thus, analysis and inference may be subject to residual bias and confounding due to unmeasured or unknown covariates. 33 We acknowledge that PS matching was incomplete in our study, failing to account for certain variables attributable to lack of consistent data availability across the 3 CHAMPION trials, including specific access site, composite bleeding risk scores, and angiographic characteristics. Although we accounted for regional differences (US limited the power of this exploratory analysis. Despite excluding patients requiring bailout GPI therapy, inherent to the study design, the results are subject to indication bias (eg, sicker patients requiring GPI therapy administered routinely may be at lower perceived bleeding risk). The overall CHAMPION program was not designed or powered to compare cangrelor with GPIs. The intention of the present analysis was to examine GPIs when used routinely as a standard of care. As such, more than 80% of the PS-matched clopidogrel-GPI group of the analyzed mITT population was enrolled from CHAMPION PCI, a trial that permitted GPI utilization for any indication. The use of GPIs by operators in CHAMPION PLATFORM and CHAMPION PHOENIX was intended to be for bailout or rescue purposes alone in the management of PCI-related thrombotic complications. However, despite these protocol specifications, a small proportion of operators continued to use GPIs as a part of routine care in these trials. Despite the variation in GPI utilization across the 3 CHAMPION trials, dedicated sensitivity analysis demonstrated the comparability of the results in the large CHAMPION PCI subset with the overall pooled analysis. Worldwide, GPI use appears to be declining, especially for routine indications; however, uptake in the United States remains robust with important regional variation. 28, 29 Figures are expressed as number / total number (rate) from the CHAMPION PCI trial. The efficacy endpoints were assessed in patients included in the modified intention-to-treat population (which comprised patients who underwent percutaneous coronary intervention and received the study drug). The safety endpoints were assessed in patients who underwent randomization and received at least one dose of the study drug. A patient who did not complete the scheduled follow-up and experienced no event was not counted in the denominator.
Abbreviations: ACUITY = Acute Catheterization and Urgent Intervention Triage Strategy; CI = confidence interval; GPI = glycoprotein IIb/IIIa inhibitors; GUSTO = Global Use of Strategies to Open Occluded Coronary Arteries; IDR = ischemia-driven revascularization; MI = myocardial infarction; OR = odds ratio; ST = stent thrombosis; TIMI = Thrombolysis in Myocardial Infarction.
